Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high2.8400 21/12/16
52 week low1.5500 18/09/17
52 week change -0.6000 (-22.86%)
4 week volume25,778,846 21/11/17

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ReNeuron losses widen

ReNeuron Group, a developer of cell-based therapeutics, made a loss of 9.57 million in the six months ended 30 September, ...

Interim results

RNS Number: 3018Z ReNeuron Group plc 14 December 2017 Details are given below of an analyst meeting and webcast at 9.30am this morning 14 December 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Interim Results for the six months ended 30 September 2017 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the develop...

Stroke clinical trial regulatory approval in US

RNS Number: 3015Z ReNeuron Group plc 14 December 2017 14 December 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Stroke clinical trial regulatory approval in US FDA approves ReNeuron's IND application to commence a Phase IIb clinical trial in the US in stroke disability ReNeuron Group plc (AIM: RENE), a global leader in the dev...

ReNeuron Group opens Boston office

ReNeuron Group has established an office in Boston that will initially house its US-based clinical, medical and scientific co...

ReNeuron opens US office

RNS Number: 7604Y ReNeuron Group plc 08 December 2017 8 December 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") ReNeuron opens US office ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it has established an office in Boston, MA, USA. This off...

Notification of Interim Results

RNS Number: 3245W ReNeuron Group plc 13 November 2017 13 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Interim Results ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , intends to announce its interim results for the six months ended 30 Septembe...

ReNeuron clinical trial enters next phase

ReNeuron Group said its retinal disease clinical trial had moved into its second phase following approval from a data safet...

Retinal disease clinical trial moves into Phase II

RNS Number: 8587V ReNeuron Group plc 08 November 2017 8 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Retinal disease clinical trial moves into Phase II Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data ReNeuron Gr...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Latest discussion posts More

  • Re: Definately cutting Edge

    I?ve also invested in VAL. My other investment being FUM
    15-Dec-2017
    Aberdeen_investor
  • Re: Definately cutting Edge

    I'm with you Aberdeen investor. I've sold 20% of my Reneuron stock and reinvested in Valirx and Physiomics. Currently doing exceptionally well .....I mean ...
    15-Dec-2017
    fredd1eboy
  • Definately cutting Edge

    Thanks for the transcript. Reneuron is definitely cutting edge science. One that can command huge premiums if all goes well. Due to the area Reneuron is conducting trials ...
    15-Dec-2017
    Aberdeen_investor

Users' HoldingsMore

Users who hold Reneuron Group also hold..

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account